Aldeyra Therapeutics: Barclays reports 5.48% stake

Aldeyra Therapeutics, Inc. (ALDX) was the subject of a Schedule 13G reporting by Barclays PLC, which reported beneficial ownership of 3,310,587 shares, or 5.48% of the class.

Available on EDGAR 11/06/2026 - 02:38 PM EST Accepted by SEC EDGAR 11/06/2026 - 02:38 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Aldeyra Therapeutics, Inc. (ALDX) was the subject of a Schedule 13G reporting by Barclays PLC, which reported beneficial ownership of 3,310,587 shares, or 5.48% of the class. Barclays PLC reported sole voting and sole dispositive power over 3,310,587 shares, with zero shared voting or dispositive power. The subsidiaries identified were Barclays Bank PLC, Barclays Capital Inc., and Barclays Capital Securities Ltd.

Key Figures

Beneficially owned: 3,310,587 shares Percent of class: 5.48% Sole voting power: 3,310,587 shares +1 more

4 metrics

Beneficially owned 3,310,587 shares Barclays PLC reported ownership

Percent of class 5.48% Barclays PLC reported ownership

Sole voting power 3,310,587 shares Barclays PLC reported ownership

Sole dispositive power 3,310,587 shares Barclays PLC reported ownership

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, Shared Voting Power

4 terms

beneficially owned regulatory

"Amount beneficially owned: 3310587"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power regulatory

"Sole Voting Power 3,310,587.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power regulatory

"Sole Dispositive Power 3,310,587.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Shared Voting Power regulatory

"Shared Voting Power 0.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ALDX shares did Barclays PLC report owning?

Barclays PLC reported beneficial ownership of 3,310,587 shares of ALDX common stock, equal to 5.48% of the class.

What voting power did Barclays PLC report for ALDX shares?

Barclays PLC reported sole voting power and sole dispositive power over 3,310,587 shares, with zero shared voting power and zero shared dispositive power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ALDEYRA THERAPEUTICS INC

(Name of Issuer)

COMMON-STOCK

(Title of Class of Securities)

01438T106

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 01438T106

1

Names of Reporting Persons

Barclays PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,310,587.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,310,587.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,310,587.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.48 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ALDEYRA THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 23 Bradford Street, MA, 02421
Item 2.
(a)	Name of person filing: Barclays PLC
(b)	Address or principal business office or, if none, residence: 1 Churchill Place, London - E14 5HP
(c)	Citizenship: X0
(d)	Title of class of securities: COMMON-STOCK
(e)	CUSIP Number(s): 01438T106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3310587
(b)	Percent of class: 5.48 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3310587
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3310587
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Barclays PLC

Signature:	Ramya Rao
Name/Title:	Director
Date:	11/06/2026